Ancotil 500 IR Tablets
Sponsors
Drugs for Neglected Diseases initiative
Conditions
Severe systemic fungal infections with susceptible pathogens
Phase 1
A COMPARATIVE BIOAVAILABILITY STUDY OF AN IMMEDIATE RELEASE TABLET FORMULATION CONTAINING 500 MG FLUCYTOSINE AND THREE SUSTAINED RELEASE PELLET FORMULATIONS OF FLUCYTOSINE IN HEALTHY SUBJECTS.
Active, not recruitingPACTR202201760181404
Start: 2022-01-27Target: 36Updated: 2026-08-03
A COMPARATIVE, SINGLE CENTER, OPEN LABEL, LABORATORY-BLIND, RANDOMIZED, SINGLE DOSE, TWO PERIOD CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF AN IMMEDIATE-RELEASE TABLET FORMULATION CONTAINING 500 MG FLUCYTOSINE AND A SUSTAINED-RELEASE PELLET FORMULATION OF FLUCYTOSINE IN HEALTHY MALES AND FEMALES UNDER FED CONDITIONS
Active, not recruitingPACTR202211836109661
Start: 2022-11-14Target: 36Updated: 2026-08-03